FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription - Concepedia

Concepedia

Publication | Open Access

FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription

DOI Full Paper Access

14

Citations

31

References

2024

Year

X. Li, Lei Gao, Bofang Wang, Jike Hu, Yang Yu, Baohong Gu, Lin Xiang, Xiaomei Li, Haiyuan Li, Tao Zhang,

Journal for ImmunoTherapy of Cancer

Abstract

FXa-activated PAR-2 promotes anoikis resistance and immune escape in HCC, suggesting the potential for combining coagulation inhibitors and PD-1/PD-L1 immune checkpoint blockade to enhance the therapeutic efficacy of HCC.

References

	Year	Citations
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel, CA A Cancer Journal for Clinicians	2021	109.5K
GSVA: gene set variation analysis for microarray and RNA-Seq data Sonja Hänzelmann, Robert Castelo, Justin Guinney BMC Bioinformatics	2013	15.6K
Pembrolizumab versus Ipilimumab in Advanced Melanoma Caroline Robert, Jacob Schachter, Georgina V. Long, New England Journal of Medicine	2015	5.7K
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer Gabriela Bindea, Bernhard Mlecnik, Marie Tosolini, Immunity Immune EvasionTumor ImmunologyCancer ImmunosurveillanceImmunologyTumor Immunity	2013	4.6K
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau, The Lancet HepatologyMedicineExpansion TrialLiver CancerAdvanced Hepatocellular Carcinoma	2017	4.2K
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma Michael A. Postow, Jason Chesney, Anna C. Pavlick, New England Journal of Medicine	2015	2.7K
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma Paul Nghiem, Shailender Bhatia, Evan J. Lipson, New England Journal of Medicine	2016	1.2K
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial Kei Muro, Hyun Cheol Chung, Veena Shankaran, The Lancet Oncology Gastrointestinal OncologyMedicinePathologyImmune Checkpoint InhibitorGastric Cancer	2016	1.1K
Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa Eric Camerer, Weitong Huang, Shaun R. Coughlin Proceedings of the National Academy of Sciences ImmunologyFactor ViiaCoagulation ProteasesInflammationThrombosis	2000	670
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma Tammy Song, Maarja-Liisa Nairismägi, Yurike Laurensia, Blood	2018	315

Page 1